Iovance Biotherapeutics

IOVA · NASDAQ

$14.86+$0.65 (+4.57%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $14.21

IOVA analyst rating

BuyConsensus of 10 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy8
Hold2
Underperform0
Sell0

12-month price target · 12 analysts

Average $13.06 (−12.1% downside)

Low: $6.06
Now: $14.86
High: $21.00

Upgrades and downgrades

The latest rating actions, newest first

IOVA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Oct 13, 2026	Maintains	Overweight	$15.00 → $18.00	46%
Baird	Oct 8, 2026	Maintains	Neutral	$6.00 → $11.00	38%
Wells Fargo	Sep 30, 2026	Maintains	Overweight	$14.00 → $18.00	32%
HC Wainwright & Co.	Sep 29, 2026	Maintains	Buy	$9.00 → $20.00	40%
Goldman Sachs	Sep 24, 2026	Initiates	Buy	$15.00	42%
Barclays	Sep 17, 2026	Maintains	Overweight	$13.00 → $15.00	46%
TD Cowen	Aug 25, 2026	Maintains	Buy	$7.00 → $10.00	67%
UBS	Aug 20, 2026	Maintains	Neutral	$4.00 → $7.00	45%
Mizuho	Aug 18, 2026	Maintains	Outperform	$10.00 → $11.00	49%
Barclays	Aug 7, 2026	Maintains	Overweight	$11.00 → $13.00	46%

The case for and against

Updated Oct 14, 2026

Bull case

Iovance Biotherapeutics is supported by a compelling combination of commercial traction and pipeline optionality, led by strong U.S. demand for AMTAGVI and Proleukin that pushed 2Q26 total revenue to about $99.3 million, up roughly 66% year over year and above expectations. Management also raised FY26 total revenue guidance to $410 million-$420 million, while expanding the authorized treatment center network to about 100 sites and targeting at least 110 by year-end, which should improve patient access and utilization. Beyond melanoma, near-complete NSCLC enrollment, SARATOGA in sarcoma, and frontline melanoma data expected at ESMO'26 create multiple catalysts, while gross margin expansion to 56% reflects improving economics from in-house manufacturing and scale.

Bear case

Iovance Biotherapeutics is viewed negatively because its value depends heavily on high-risk clinical success, yet its autologous TIL assets may still fail to show sufficient efficacy or superiority against established metastatic melanoma therapies and emerging CAR-T competition. The company also faces substantial regulatory uncertainty, since U.S. and foreign approvals are required and any failure or delay would materially hurt commercialization prospects and investor sentiment. Despite a strong cash position, it continues to spend heavily on R&D and may need additional capital from equity or non-dilutive sources, while one bear case cited lifileucel’s weak uptake in early 2026 and only a 10% probability of commercial success.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.